Indaptus Therapeutics (NASDAQ:INDP) Trading 0.6% Higher

Posted by Defense World Staff on Apr 13th, 2023

Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating)’s stock price traded up 0.6% on Wednesday . The stock traded as high as $1.81 and last traded at $1.81. 748 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 7,618 shares. The stock had previously closed at $1.80.

Analyst Ratings Changes

Separately, HC Wainwright lowered their target price on shares of Indaptus Therapeutics from $15.00 to $12.00 in a report on Monday, March 20th.

Indaptus Therapeutics Stock Up 0.6 %

The firm has a market cap of $15.21 million, a PE ratio of -1.05 and a beta of 0.98. The company’s fifty day moving average price is $1.72 and its two-hundred day moving average price is $1.76.

Institutional Trading of Indaptus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in INDP. Strategy Asset Managers LLC purchased a new stake in Indaptus Therapeutics during the third quarter worth about $120,000. Vanguard Group Inc. boosted its holdings in Indaptus Therapeutics by 18.7% during the first quarter. Vanguard Group Inc. now owns 242,235 shares of the company’s stock worth $969,000 after buying an additional 38,216 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Indaptus Therapeutics in the second quarter valued at about $51,000. State Street Corp purchased a new stake in shares of Indaptus Therapeutics in the first quarter valued at about $78,000. Finally, Northern Trust Corp purchased a new stake in shares of Indaptus Therapeutics in the first quarter valued at about $41,000. Hedge funds and other institutional investors own 6.87% of the company’s stock.

Indaptus Therapeutics Company Profile

(Get Rating)

Indaptus Therapeutics, Inc is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria.

Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.